Patents by Inventor Subhashini Arimilli

Subhashini Arimilli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for assessing risk of substance administration
    Patent number: 10309956
    Abstract: A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 4, 2019
    Assignees: R.J. Reynolds Tobacco Company, Wake Forest University Health Sciences
    Inventors: Gaddamanugu L. Prasad, Subhashini Arimilli
  • PROCESS FOR ASSESSING RISK OF SUBSTANCE ADMINISTRATION
    Publication number: 20160025705
    Abstract: A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 28, 2016
    Inventors: GADDAMANUGU L. PRASAD, Subhashini Arimilli
  • Identification of potential immunodominant acetylcholine receptor alpha subunit
    Publication number: 20050048066
    Abstract: The present invention is directed to the treatment of autoimmune diseases, in particular of Myasthenia Gravis. This invention provides novel autoimmune dominant peptides derived from the acetylcholine receptor, as well as methods for preparing the peptides. The present invention further provides complexes comprising these peptides associated with an appropriate major histocompatibility complex (MHC) molecule and methods for making these complexes. The complexes of the present invention can be used therapeutically or prophylactically for treating Myasthenia Gravis.
    Type: Application
    Filed: March 30, 2001
    Publication date: March 3, 2005
    Inventors: Shrikant Deshpande, Edward Spack, Nancy Wehner, Subhashini Arimilli
  • Immunodominant acetylcholine receptor alpha subunit peptide: MHC complexes
    Publication number: 20030144477
    Abstract: The present invention is directed to the treatment of autoimmune diseases, in particular of myasthenia gravis. This invention provides novel autoimmune dominant peptides derived from the acetylcholine receptor, as well as methods for preparing the peptides. The present invention further provides complexes comprising these peptides associated with an appropriate major histocompatibility complex (MHC) molecule and methods for making these complexes. The complexes of the present invention can be used therapeutically or prophylactically for treating myasthenia gravis.
    Type: Application
    Filed: September 30, 2002
    Publication date: July 31, 2003
    Applicant: Corixa Corporation
    Inventors: Edward Spack, Subhashini Arimilli, Shrikant Deshpande, Nancy Wehner
  • HLA-DR2 binding peptides
    Publication number: 20030103993
    Abstract: The invention provides a polypeptide sequence, GHIKSSISFMGM, that disrupts binding of the amino acid sequence peptides of myelin basic protein (MBP) to HLA-DR2 class II MHC molecules and acts as an antagonist in DR2-restricted antigen presentation to human T cell clones. In particular, the invention provides the polypeptide sequence itself and variants, compositions comprising the polypeptide, polynucleotides encoding the polypeptide, and methods for using the polypeptides and polynucleotides for treating autoimmune disorders.
    Type: Application
    Filed: December 12, 2001
    Publication date: June 5, 2003
    Applicant: Corixa Corporation
    Inventors: Shrikant Deshpande, Subhashini Arimilli, Kalidip Choudhury
  • Immune mediators and related methods
    Publication number: 20020082411
    Abstract: The present invention relates to nucleic acids encoding single chain MHC class II molecules that form multimers via inter-chain multimerization domains, and methods of treating autoimmune disease using the same.
    Type: Application
    Filed: March 22, 2001
    Publication date: June 27, 2002
    Inventors: Darrick Carter, Shirley Zhu, Subhashini Arimilli, Aijun Wang
  • Methods for treating disease with antibodies to CXCR3
    Publication number: 20020039578
    Abstract: The present invention provides antibodies directed against the CXCR3 chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory diseases and conditions.
    Type: Application
    Filed: March 27, 2001
    Publication date: April 4, 2002
    Inventors: Subhashini Arimilli, Walter Ferlin, Shrikant Deshpande, Simonetta Mocci
  • Chemokine receptor peptide vaccines for treatment and prevention of diabetes
    Publication number: 20010006942
    Abstract: The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.
    Type: Application
    Filed: January 4, 2001
    Publication date: July 5, 2001
    Inventors: Maureen Howard, Shrikant Deshpande, Walter Ferlin, Subhashini Arimilli
  • Chemokine receptor peptide for inducing an immune response
    Patent number: 6171590
    Abstract: The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: January 9, 2001
    Assignee: Corixa Corporation
    Inventors: Maureen Howard, Shrikant Deshpande, Walter Ferlin, Subhashini Arimilli